ESTRO Brachytherapy for Prostate Cancer 2018

710 / 884

Disease progression free survival dependent
on PSA level, preoperativ parameter
< 4ng/ml → 5 years progression
free probabiity
86%
Cancer survival < 10ng/ml vs
>10ng/ml → 10 years
vs.55%
vs.28%
Bianco FJ IJROBP 2005